2[1]Grau AJ,Ruf A,vogt A,et al.Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia.Thromb haemost,1998,80:298-301.
3[2]Ruf A,Patscheke H.Flow cytometric detection of activated platelets:comparison of determining shape change,fibrinogen binding and P-selectin expression.Semin Thromb Hemost,1995,21:146-151.
4[4]Michelson AD.Flow cytometry:a clinical test of platelet function.Blood,1996,87:4925-4936.
5[5]Shattil SJ,Hoie JA,Cunning M,et al.Changes in the platelet membrane glycoprotein Ⅱb-Ⅲa complex during platelet activation.J Biol chem,1985,260:11107-11114.
6[6]Michelson AD.Flow cytometry assessment of glycoprotein movements in platelets.Platelets,1997,8:105-115.
7[7]Abrams C,Shattil SJ.Immunological detection of activation platelets in clinical disorder.Thromb Haemost,1991,65:467-650.
8[8]Michelson AD,Barnard MR,Hechtman HB,et al.In vivo tracting of platelets:circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.Porch Natl Acad Sci USA,1996,93:11877-11882.
9[1]Michelson AD. Flow cytometry: A clinical test of platelet function.Blood, 1996,87(12) :4925～4936
10[2]Corash L. Measurement of platelet activation of fluorescence activated flow cytometry. Blood cell, 1999,16( 1 ) :97～106
2Antoniucci D, Valenti R, Migliorini A, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J,2001,142 :684-690.
3Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J,2003,145:42-46.
4Kubica J, Kozinski M. No-reflow phenomenon : Achilles' heel of primary coronary angioplasty in acute myocardial infarction. Cardiol J,2008,15 : 1-3.
5Abbate A, Kontos MC, Biondi-Zoccai GG. No - reflow : the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J, 2008,29 : 1795-1797.
6Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the noreflow phenomenon after percutaneous coronary, intervention. Circulation, 2008,117:3152-3156.
7Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol,2005,95:1358-1361.
8Mukherjee D,Oz M, Prager R, et al. Elective coronary revascularization, an iatrogenic form of acute coronary syndrome:how can clinicians reduce the risks? Am Heart J,2004,148:371-377.
9Pasceri V, Patti G, Di Sciascio G. Prevention of myocardial damage during coronary intervention. Cardiovasc Hematol Disord Drug Targets,2006,6: 77-83.
10Ehzschig HK,Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation:coordina- tion by extracellular nucleotide metabolism. Blood, 2004, 104 : 3986- 3992.
